| Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis A Kindmark, A Jawaid, CG Harbron, BJ Barratt, OF Bengtsson, ... The pharmacogenomics journal 8 (3), 186-195, 2008 | 410 | 2008 |
| Evaluating robustness and sensitivity of the NanoString technologies nCounter platform to enable multiplexed gene expression analysis of clinical samples MH Veldman-Jones, R Brant, C Rooney, C Geh, H Emery, CG Harbron, ... Cancer research 75 (13), 2587-2593, 2015 | 367 | 2015 |
| Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244) JR Dry, S Pavey, CA Pratilas, C Harbron, S Runswick, D Hodgson, ... Cancer research 70 (6), 2264-2273, 2010 | 268 | 2010 |
| Covert manipulation of the ratio of medium-to long-chain triglycerides in isoenergetically dense diets: effect on food intake in ad libitum feeding men. RJ Stubbs, CG Harbron International journal of obesity and related metabolic disorders: journal of …, 1996 | 146 | 1996 |
| Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease J Armstrong, C Harbron, S Lea, G Booth, P Cadden, KA Wreggett, ... Journal of Pharmacology and Experimental Therapeutics 338 (3), 732-740, 2011 | 102 | 2011 |
| Reproducible, quantitative, and flexible molecular subtyping of clinical DLBCL samples using the NanoString nCounter system MH Veldman-Jones, Z Lai, M Wappett, CG Harbron, JC Barrett, ... Clinical cancer research 21 (10), 2367-2378, 2015 | 81 | 2015 |
| Embracing model-based designs for dose-finding trials SB Love, S Brown, CJ Weir, C Harbron, C Yap, B Gaschler-Markefski, ... British journal of cancer 117 (3), 332-339, 2017 | 77 | 2017 |
| Personalized medicine and proteomics: lessons from non-small cell lung cancer G Marko-Varga, A Ogiwara, T Nishimura, T Kawamura, K Fujii, ... Journal of proteome research 6 (8), 2925-2935, 2007 | 70 | 2007 |
| Synthetic data use: exploring use cases to optimise data utility S James, C Harbron, J Branson, M Sundler Discover Artificial Intelligence 1 (1), 15, 2021 | 68 | 2021 |
| In search of preclinical robustness IS Peers, PR Ceuppens, C Harbron Nature reviews Drug discovery 11 (10), 733-734, 2012 | 66 | 2012 |
| The use of external controls: To what extent can it currently be recommended? HU Burger, C Gerlinger, C Harbron, A Koch, M Posch, J Rochon, A Schiel Pharmaceutical Statistics 20 (6), 1002-1016, 2021 | 58 | 2021 |
| Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 … C Pott, E Hoster, B Kehden, M Unterhalt, M Herold, RH van der Jagt, ... Blood 128 (22), 613, 2016 | 55 | 2016 |
| RefPlus: an R package extending the RMA Algorithm C Harbron, KM Chang, MC South Bioinformatics 23 (18), 2493-2494, 2007 | 54 | 2007 |
| A statistician's perspective on biomarkers in drug development M Jenkins, A Flynn, T Smart, C Harbron, T Sabin, J Ratnayake, P Delmar, ... Pharmaceutical statistics 10 (6), 494-507, 2011 | 46 | 2011 |
| Learning from data with structured missingness R Mitra, SF McGough, T Chakraborti, C Holmes, R Copping, ... Nature Machine Intelligence 5 (1), 13-23, 2023 | 36 | 2023 |
| A flexible unified approach to the analysis of pre‐clinical combination studies C Harbron Statistics in medicine 29 (16), 1746-1756, 2010 | 36 | 2010 |
| Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data R Liu, S Rizzo, S Waliany, MR Garmhausen, N Pal, Z Huang, ... Nature Medicine 28 (8), 1656-1661, 2022 | 35 | 2022 |
| P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells S Lea, J Li, J Plumb, K Gaffey, S Mason, R Gaskell, C Harbron, D Singh Journal of Molecular Medicine 98, 361-374, 2020 | 35 | 2020 |
| MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial C Pott, LH Sehn, D Belada, J Gribben, E Hoster, B Kahl, B Kehden, ... Leukemia 34 (2), 522-532, 2020 | 33 | 2020 |
| Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen‐activated protein kinase (MAPK) inhibitor S Lea, C Harbron, N Khan, G Booth, J Armstrong, D Singh British journal of clinical pharmacology 79 (5), 756-766, 2015 | 32 | 2015 |
